Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | MMP9 | P14780 | 4/20 | 0.33 |
| ▸ | MMP8 | P22894 | 4/20 | 0.33 |
| ▸ | MMP13 | P45452 | 4/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26488594 | 1.00 | CNR1 (0.35) | CNR1CNR2MMP2MMP9MMP8 | |
| SCHEMBL24285478 | 0.93 | PDK2 (0.40) | CNR1CNR2MMP2MMP9MMP8 | |
| SCHEMBL28386971 | 0.93 | PDK2 (0.40) | CNR1CNR2MMP2MMP9MMP8 | |
| SCHEMBL26489849 | 0.89 | CNR1 (0.30) | CNR1CNR2 | |
| SCHEMBL12962387 | 0.89 | LIPG (0.38) | CNR1CNR2 | |
| SCHEMBL29272574 | 0.79 | TP53 (0.45) | CNR1CNR2 | |
| SCHEMBL28852732 | 0.79 | TP53 (0.45) | CNR1CNR2 | |
| SCHEMBL16261010 | 0.78 | PDK2 (0.33) | CNR1CNR2PDK2 | |
| SCHEMBL21531690 | 0.78 | PDK2 (0.33) | CNR1CNR2PDK2 | |
| SCHEMBL19442933 | 0.77 | CNR1 (0.40) | CNR1CNR2MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | PHOSPHO1, SGMS1, PLIN3 | CNR1 3929/4885CNR2 4312/4885MMP2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.